Evidence map›Paper›PMID 34138471›Full record

Trial reportCancer2021

Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Koji Sasaki, Hagop M Kantarjian, Kiyomi Morita, Nicholas J Short, Marina Konopleva, Nitin Jain, Farhad Ravandi, Guillermo Garcia-Manero, Sa Wang, Joseph D Khoury and 10 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. How I treat newly diagnosed acute lymphoblastic leukemia.Clinical hematology international · 2024
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Therapeutic Advances in Immunotherapies for Hematological Malignancies.International journal of molecular sciences · 2022
    Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Koji SasakiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9140-0610
Hagop M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kiyomi MoritaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0407-1565
Nicholas J ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2983-2738
Marina KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3631-2482
Sa WangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Joseph D KhouryDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jeffrey L JorgensenDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Richard E ChamplinDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Issa F KhouriDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Partow KebriaeiDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Heather M SchroederDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maria KhouriDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Rebecca GarrisDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Koichi TakahashiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Susan M O'BrienDivision of Hematology/Oncology, Department of Medicine, UCI Health, Orange, California.
Elias J JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4465-6119
The University of Texas MD Anderson Cancer Center · USUC Irvine Health · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672Novartis Pharma
6 · The paper itself

Abstract

backgroundThe outcome of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone plus ofatumumab hyper-CVAD + ofatumumab (hyper-CVAD + ofatumumab) has not been compared with the outcome of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone plus ofatumumab hyper-CVAD plus rituximab (hyper-CVAD + Rituximab) in Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in a randomized clinical trial.

methodsThe authors compared the outcomes of 69 patients treated with hyper-CVAD + ofatumumab and 95 historical-control patients treated with hyper-CVAD + Rituximab. Historical-control patients were treated with hyper-CVAD + Rituximab if they had CD20 expression ≥ 20%. Ofatumumab (day 1 of course 1, 300 mg intravenously; subsequent doses, 2000 mg intravenously) was administered on days 1 and 11 of courses 1 and 3 and on days 1 and 8 of courses 2 and 4 for a total of 8 doses. A propensity score analysis with inverse probability of treatment weighting (IPTW) was performed to adjust for baseline covariates between groups.

resultsThe median event-free survival with stem cell transplantation (SCT) censoring was 33 and 65 months with hyper-CVAD + Rituximab and hyper-CVAD + ofatumumab, respectively (crude P = .064; IPTW P = .054). The median overall survival with SCT censoring was 52 months and not reached, respectively (crude P = .087; IPTW P = .097).

conclusionsHyper-CVAD + ofatumumab was associated with better outcomes than hyper-CVAD + Rituximab among patients with newly diagnosed Philadelphia chromosome-negative ALL.

Indexed as

Philadelphia ChromosomePrecursor Cell Lymphoblastic Leukemia-LymphomaAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDexamethasoneDoxorubicinHumansPropensity ScoreRituximabVincristineAntibodies, Monoclonal, HumanizedCyclophosphamideDexamethasoneDoxorubicinofatumumabRituximabVincristineacute lymphoblastic leukemiaanti-CD20 antibodyofatumumabPhiladelphia chromosome-negative

Identifiers

PMID34138471
PMCPMC11849228
OpenAlexW3166547746

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.